Therefore, we suggest that dual activation of ERβ and PGR by their ligands could initiate a cascade of cellular anti-cancer events involving inhibition of cancer progression induced via AR (15, 27) and ERα (57, 59) pathways alongside promoting anti-proliferative and pro-apoptotic activities (31, 60). The gene discussed is ESR2; the disease is cancer.